Evidence map›Paper›PMID 35057527›Full record

Observational studyNutrients2022

Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS).

Shota Matsufuji, Tetsuo Shoji, Suhye Lee, Masao Yamaguchi, Mari Nishimura, Yoshihiro Tsujimoto, Shinya Nakatani, Tomoaki Morioka, Katsuhito Mori, Masanori Emoto

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Observational
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Shota MatsufujiDivision of Rehabilitation, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, Japan.
Tetsuo ShojiDepartment of Vascular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.ORCID 0000-0003-3953-0925
Suhye LeeDivision of Rehabilitation, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, Japan.
Masao YamaguchiDivision of Rehabilitation, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, Japan.
Mari NishimuraDivision of Rehabilitation, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, Japan.
Yoshihiro TsujimotoDivision of Internal Medicine, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, Japan.
Shinya NakataniDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
Tomoaki MoriokaDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.ORCID 0000-0002-2329-8191
Katsuhito MoriDepartment of Nephrology, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.ORCID 0000-0002-0085-0828
Masanori EmotoVascular Science Center for Translational Research, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
Inoue Hospital · JPOsaka City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carnitine deficiency is prevalent in patients undergoing hemodialysis, and it could result in lowered muscle strength. So far, the effect of treatment with levocarnitine on lower limb muscle strength has not been well described. This observational study examined the association between treatment with levocarnitine with the change in knee extensor strength (KES) in hemodialysis patients. Eligible patients were selected from the participants enrolled in a prospective cohort study for whom muscle strength was measured annually. We identified 104 eligible patients for this analysis. During the one-year period between 2014 to 2015, 67 patients were treated with intravenous levocarnitine (1000 mg per shot, thrice weekly), whereas 37 patients were not. The change in KES was significantly higher (

Indexed as

Administration, IntravenousAgedCardiomyopathiesCarnitineFemaleHumansHyperammonemiaKneeMaleMiddle AgedMuscle StrengthMuscular DiseasesProspective StudiesRegression AnalysisRenal DialysisTreatment OutcomeCarnitinecarnitine deficiencyfrailtyhemodialysismuscle strengthsarcopenia

Identifiers

PMID35057527
PMCPMC8782050
OpenAlexW4206607401

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.